NeuroPace Reports Positive Results of Next-Gen RNS System for Refractory Epilepsy in the US

Shots:

• The results are concluded from 9 years’ study evaluating Next-Gen RNS System in 256 patients at 33 epilepsy centers, lacking adequate response to medications
• The study demonstrated in 50% (3/4), 90% (1/3) reduction in seizures, median seizure reduction was 75%, six months or longer seizure-free periods 28%, seizure-free periods of one year or longer 18%, with improved QoL
• Next-Gen RNS System is a FDA approved closed loop brain-responsive neurostimulation device with brain-computer interface, for continuous monitoring of brain waves recognizing each patient’s unique seizure onset pattern sending electrical pulses

Click here to read full press release/ article | Ref: Neuropace| Image: NeuroPace, Inc